Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Sarcoidosis | 9 | 2024 | 539 | 4.270 |
Why?
|
Cardiomyopathies | 10 | 2024 | 2056 | 2.590 |
Why?
|
Peripheral Arterial Disease | 5 | 2024 | 1299 | 1.800 |
Why?
|
Myocarditis | 4 | 2023 | 804 | 1.620 |
Why?
|
Fractional Flow Reserve, Myocardial | 9 | 2024 | 347 | 1.450 |
Why?
|
Myocardial Perfusion Imaging | 11 | 2024 | 672 | 1.420 |
Why?
|
Fluorodeoxyglucose F18 | 8 | 2023 | 2048 | 1.360 |
Why?
|
Positron-Emission Tomography | 21 | 2024 | 6657 | 1.230 |
Why?
|
Eosinophilic Granuloma | 2 | 2017 | 27 | 1.160 |
Why?
|
Coronary Artery Disease | 20 | 2024 | 6551 | 1.160 |
Why?
|
Respiratory Sounds | 2 | 2017 | 702 | 0.840 |
Why?
|
Coronary Circulation | 12 | 2024 | 1617 | 0.710 |
Why?
|
Anthracyclines | 1 | 2022 | 286 | 0.700 |
Why?
|
Myocardial Infarction | 15 | 2024 | 11515 | 0.690 |
Why?
|
Exercise Therapy | 2 | 2024 | 941 | 0.680 |
Why?
|
Ventricular Function, Left | 7 | 2024 | 3941 | 0.630 |
Why?
|
Radiopharmaceuticals | 6 | 2023 | 2731 | 0.600 |
Why?
|
Nitrogen Oxides | 1 | 2017 | 129 | 0.580 |
Why?
|
Ultrasonography, Interventional | 2 | 2022 | 1519 | 0.560 |
Why?
|
Nitroglycerin | 1 | 2017 | 332 | 0.540 |
Why?
|
Lipoprotein(a) | 5 | 2024 | 488 | 0.530 |
Why?
|
Cardiovascular System | 1 | 2023 | 838 | 0.530 |
Why?
|
Heart Transplantation | 2 | 2019 | 3291 | 0.500 |
Why?
|
Angioplasty, Balloon | 1 | 2019 | 592 | 0.500 |
Why?
|
Exercise Test | 4 | 2021 | 2186 | 0.500 |
Why?
|
Burnout, Professional | 2 | 2020 | 712 | 0.480 |
Why?
|
Diabetic Angiopathies | 1 | 2019 | 806 | 0.460 |
Why?
|
Cardiology | 2 | 2023 | 1701 | 0.460 |
Why?
|
Registries | 14 | 2024 | 8373 | 0.440 |
Why?
|
Medicare | 4 | 2024 | 6881 | 0.420 |
Why?
|
Coronary Angiography | 8 | 2023 | 4526 | 0.410 |
Why?
|
Cardiovascular Agents | 1 | 2017 | 849 | 0.370 |
Why?
|
Cardiovascular Diseases | 7 | 2024 | 15638 | 0.360 |
Why?
|
Humans | 76 | 2024 | 768451 | 0.330 |
Why?
|
Ventricular Remodeling | 4 | 2022 | 1280 | 0.330 |
Why?
|
Thrombosis | 2 | 2022 | 2956 | 0.320 |
Why?
|
Heart Failure | 6 | 2023 | 11857 | 0.320 |
Why?
|
Lung | 2 | 2017 | 10090 | 0.310 |
Why?
|
Endovascular Procedures | 1 | 2022 | 2258 | 0.310 |
Why?
|
Glucose | 1 | 2019 | 4355 | 0.290 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2022 | 3253 | 0.290 |
Why?
|
Stroke Volume | 6 | 2024 | 5620 | 0.280 |
Why?
|
Microcirculation | 4 | 2024 | 1282 | 0.260 |
Why?
|
Diabetes Mellitus | 3 | 2024 | 5887 | 0.260 |
Why?
|
Coronary Vessels | 6 | 2024 | 3122 | 0.260 |
Why?
|
Pre-Eclampsia | 2 | 2024 | 1257 | 0.240 |
Why?
|
Calcium | 3 | 2021 | 5793 | 0.230 |
Why?
|
Cough | 2 | 2017 | 598 | 0.210 |
Why?
|
Internship and Residency | 2 | 2020 | 5952 | 0.210 |
Why?
|
Plaque, Atherosclerotic | 1 | 2014 | 1547 | 0.210 |
Why?
|
Tomography, X-Ray Computed | 7 | 2022 | 20762 | 0.210 |
Why?
|
Heart | 3 | 2021 | 4451 | 0.210 |
Why?
|
Predictive Value of Tests | 7 | 2024 | 15460 | 0.210 |
Why?
|
Insurance Benefits | 1 | 2024 | 187 | 0.210 |
Why?
|
Systemic Vasculitis | 1 | 2023 | 37 | 0.210 |
Why?
|
Prednisone | 2 | 2017 | 1568 | 0.200 |
Why?
|
Respiratory Function Tests | 2 | 2017 | 1697 | 0.200 |
Why?
|
Aged | 23 | 2024 | 171520 | 0.200 |
Why?
|
Topoisomerase II Inhibitors | 1 | 2022 | 94 | 0.200 |
Why?
|
Retrospective Studies | 26 | 2024 | 81834 | 0.200 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 2 | 2024 | 1142 | 0.200 |
Why?
|
Atherosclerosis | 3 | 2024 | 3431 | 0.190 |
Why?
|
United States | 9 | 2024 | 73121 | 0.190 |
Why?
|
Female | 42 | 2024 | 396943 | 0.190 |
Why?
|
Radioisotopes | 1 | 2023 | 516 | 0.190 |
Why?
|
Cicatrix | 2 | 2024 | 799 | 0.190 |
Why?
|
Immunoglobulin E | 2 | 2017 | 1510 | 0.180 |
Why?
|
Vascular Resistance | 1 | 2024 | 941 | 0.180 |
Why?
|
Myocardial Ischemia | 2 | 2023 | 2139 | 0.180 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2024 | 560 | 0.180 |
Why?
|
Prognosis | 9 | 2024 | 30028 | 0.180 |
Why?
|
Myeloid-Lymphoid Leukemia Protein | 1 | 2023 | 308 | 0.170 |
Why?
|
D-Amino-Acid Oxidase | 1 | 2019 | 26 | 0.170 |
Why?
|
Hypertension | 4 | 2024 | 8611 | 0.160 |
Why?
|
Intermittent Claudication | 1 | 2021 | 305 | 0.160 |
Why?
|
Middle Aged | 32 | 2024 | 223418 | 0.160 |
Why?
|
Treatment Outcome | 8 | 2024 | 65409 | 0.160 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2022 | 679 | 0.150 |
Why?
|
Male | 36 | 2024 | 364781 | 0.150 |
Why?
|
Thoracic Neoplasms | 1 | 2020 | 270 | 0.150 |
Why?
|
Aortic Valve Stenosis | 2 | 2022 | 2032 | 0.150 |
Why?
|
Glucocorticoids | 2 | 2017 | 2170 | 0.150 |
Why?
|
Cardiology Service, Hospital | 1 | 2019 | 241 | 0.150 |
Why?
|
Drug Administration Routes | 1 | 2017 | 151 | 0.150 |
Why?
|
Copper | 1 | 2019 | 368 | 0.140 |
Why?
|
Angiotensin II Type 1 Receptor Blockers | 1 | 2019 | 429 | 0.130 |
Why?
|
Duodenum | 1 | 2019 | 495 | 0.130 |
Why?
|
Atrial Appendage | 1 | 2020 | 285 | 0.130 |
Why?
|
Minority Groups | 1 | 2023 | 1215 | 0.130 |
Why?
|
Hypolipidemic Agents | 1 | 2020 | 609 | 0.130 |
Why?
|
Healthcare Disparities | 2 | 2023 | 3412 | 0.130 |
Why?
|
Renal Insufficiency, Chronic | 3 | 2024 | 2291 | 0.130 |
Why?
|
Constriction, Pathologic | 1 | 2019 | 1103 | 0.130 |
Why?
|
Prospective Studies | 6 | 2024 | 54914 | 0.130 |
Why?
|
Hydrogen Peroxide | 1 | 2019 | 742 | 0.130 |
Why?
|
Protease Inhibitors | 1 | 2019 | 753 | 0.130 |
Why?
|
Tachycardia, Ventricular | 1 | 2024 | 1309 | 0.120 |
Why?
|
Zinc | 1 | 2019 | 677 | 0.120 |
Why?
|
Fungal Proteins | 1 | 2019 | 908 | 0.120 |
Why?
|
Coronary Disease | 3 | 2019 | 5926 | 0.120 |
Why?
|
Risk Factors | 14 | 2024 | 74915 | 0.120 |
Why?
|
Cocaine-Related Disorders | 1 | 2018 | 461 | 0.120 |
Why?
|
Out-of-Hospital Cardiac Arrest | 1 | 2018 | 340 | 0.120 |
Why?
|
Incidence | 6 | 2024 | 21552 | 0.120 |
Why?
|
Radiosurgery | 1 | 2024 | 1354 | 0.120 |
Why?
|
Breast Neoplasms | 1 | 2021 | 21156 | 0.110 |
Why?
|
Recurrence | 2 | 2024 | 8510 | 0.110 |
Why?
|
Walking | 1 | 2021 | 1202 | 0.110 |
Why?
|
Diagnosis, Differential | 3 | 2019 | 13026 | 0.110 |
Why?
|
Patient Care | 1 | 2019 | 629 | 0.110 |
Why?
|
Marijuana Abuse | 1 | 2018 | 412 | 0.110 |
Why?
|
Workload | 1 | 2019 | 852 | 0.110 |
Why?
|
Tetrazoles | 1 | 2019 | 922 | 0.110 |
Why?
|
Cardiomyopathy, Dilated | 1 | 2019 | 843 | 0.110 |
Why?
|
Inflammation | 3 | 2023 | 10865 | 0.110 |
Why?
|
Guidelines as Topic | 1 | 2019 | 1395 | 0.110 |
Why?
|
Neoplasms | 1 | 2021 | 22386 | 0.100 |
Why?
|
Patient Admission | 1 | 2019 | 1370 | 0.100 |
Why?
|
Boston | 3 | 2019 | 9361 | 0.100 |
Why?
|
Academic Medical Centers | 2 | 2019 | 2785 | 0.100 |
Why?
|
Psoriasis | 1 | 2020 | 947 | 0.100 |
Why?
|
Drug Combinations | 3 | 2023 | 2079 | 0.100 |
Why?
|
Magnetic Resonance Imaging | 1 | 2019 | 36840 | 0.100 |
Why?
|
Celiac Disease | 1 | 2019 | 819 | 0.090 |
Why?
|
Young Adult | 6 | 2022 | 60045 | 0.090 |
Why?
|
Treatment Failure | 1 | 2017 | 2656 | 0.090 |
Why?
|
Echocardiography | 1 | 2024 | 5043 | 0.090 |
Why?
|
Catheter Ablation | 1 | 2024 | 2775 | 0.090 |
Why?
|
Myocardium | 2 | 2024 | 4788 | 0.090 |
Why?
|
Tomography, Optical Coherence | 1 | 2024 | 2958 | 0.090 |
Why?
|
Stents | 1 | 2022 | 3204 | 0.090 |
Why?
|
Myocytes, Cardiac | 1 | 2019 | 1683 | 0.090 |
Why?
|
Risk Assessment | 7 | 2024 | 24311 | 0.080 |
Why?
|
Recovery of Function | 1 | 2020 | 2994 | 0.080 |
Why?
|
Adult | 17 | 2024 | 223542 | 0.080 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2020 | 2145 | 0.080 |
Why?
|
Bone Marrow | 1 | 2019 | 2929 | 0.080 |
Why?
|
Time Factors | 5 | 2024 | 40271 | 0.080 |
Why?
|
Gene Expression Profiling | 1 | 2024 | 9507 | 0.080 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2021 | 2173 | 0.080 |
Why?
|
Kidney Transplantation | 1 | 2024 | 4285 | 0.080 |
Why?
|
Smoking Cessation | 1 | 2020 | 2079 | 0.080 |
Why?
|
Age Factors | 3 | 2019 | 18478 | 0.080 |
Why?
|
Asthma | 2 | 2017 | 6274 | 0.080 |
Why?
|
Oxidative Stress | 1 | 2019 | 3145 | 0.070 |
Why?
|
Education, Medical, Graduate | 1 | 2019 | 2411 | 0.070 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2023 | 3623 | 0.070 |
Why?
|
Hospitals | 1 | 2019 | 3906 | 0.070 |
Why?
|
Aged, 80 and over | 4 | 2024 | 59680 | 0.060 |
Why?
|
Follow-Up Studies | 7 | 2022 | 39430 | 0.060 |
Why?
|
Cohort Studies | 4 | 2022 | 41797 | 0.060 |
Why?
|
Biomedical Research | 1 | 2020 | 3463 | 0.060 |
Why?
|
Cardiac Surgical Procedures | 1 | 2020 | 3682 | 0.060 |
Why?
|
Mortality | 3 | 2021 | 2917 | 0.060 |
Why?
|
Aminopeptidases | 1 | 2024 | 113 | 0.060 |
Why?
|
Sensitivity and Specificity | 1 | 2019 | 14728 | 0.060 |
Why?
|
Disease Management | 1 | 2014 | 2533 | 0.060 |
Why?
|
Heart Aneurysm | 1 | 2024 | 114 | 0.060 |
Why?
|
Dideoxynucleosides | 1 | 2023 | 135 | 0.050 |
Why?
|
Reproducibility of Results | 2 | 2019 | 20231 | 0.050 |
Why?
|
Age of Onset | 2 | 2021 | 3342 | 0.050 |
Why?
|
Lamivudine | 1 | 2023 | 368 | 0.050 |
Why?
|
Proportional Hazards Models | 3 | 2022 | 12561 | 0.050 |
Why?
|
Health Services Accessibility | 1 | 2019 | 5510 | 0.050 |
Why?
|
Ammonia | 1 | 2022 | 249 | 0.050 |
Why?
|
Oxazines | 1 | 2023 | 357 | 0.050 |
Why?
|
Atrial Fibrillation | 1 | 2020 | 5162 | 0.050 |
Why?
|
Massachusetts | 3 | 2020 | 8908 | 0.050 |
Why?
|
Drug Substitution | 1 | 2023 | 291 | 0.050 |
Why?
|
Alanine | 1 | 2023 | 613 | 0.050 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2023 | 295 | 0.050 |
Why?
|
Diagnostic Imaging | 1 | 2014 | 3543 | 0.040 |
Why?
|
Anemia, Hypochromic | 1 | 2019 | 63 | 0.040 |
Why?
|
Case-Control Studies | 3 | 2023 | 22293 | 0.040 |
Why?
|
Microvessels | 1 | 2024 | 586 | 0.040 |
Why?
|
Hospitalization | 1 | 2019 | 10845 | 0.040 |
Why?
|
Bone Marrow Examination | 1 | 2019 | 155 | 0.040 |
Why?
|
Mendelian Randomization Analysis | 1 | 2024 | 1036 | 0.040 |
Why?
|
Histone-Lysine N-Methyltransferase | 1 | 2023 | 697 | 0.040 |
Why?
|
Pyridones | 1 | 2023 | 819 | 0.040 |
Why?
|
Retinal Vessels | 1 | 2024 | 864 | 0.040 |
Why?
|
Mitochondria, Heart | 1 | 2019 | 236 | 0.040 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2023 | 1339 | 0.040 |
Why?
|
Cause of Death | 2 | 2021 | 3727 | 0.040 |
Why?
|
Neovascularization, Physiologic | 1 | 2024 | 1369 | 0.040 |
Why?
|
Myocardial Revascularization | 1 | 2021 | 796 | 0.040 |
Why?
|
Injections, Intravenous | 1 | 2019 | 1379 | 0.030 |
Why?
|
HIV Infections | 1 | 2023 | 17564 | 0.030 |
Why?
|
Postpartum Period | 1 | 2024 | 1197 | 0.030 |
Why?
|
Shock, Cardiogenic | 1 | 2022 | 711 | 0.030 |
Why?
|
Hospital Mortality | 2 | 2022 | 5371 | 0.030 |
Why?
|
Vasodilator Agents | 1 | 2021 | 991 | 0.030 |
Why?
|
Nausea | 1 | 2019 | 682 | 0.030 |
Why?
|
Neprilysin | 1 | 2019 | 487 | 0.030 |
Why?
|
Medically Uninsured | 1 | 2021 | 841 | 0.030 |
Why?
|
Survival Rate | 2 | 2020 | 12875 | 0.030 |
Why?
|
Rats, Wistar | 1 | 2019 | 1891 | 0.030 |
Why?
|
Up-Regulation | 1 | 2024 | 4138 | 0.030 |
Why?
|
Troponin T | 1 | 2019 | 787 | 0.030 |
Why?
|
Dependovirus | 1 | 2019 | 720 | 0.030 |
Why?
|
Biphenyl Compounds | 1 | 2019 | 1026 | 0.030 |
Why?
|
Reoperation | 1 | 2024 | 4342 | 0.030 |
Why?
|
Hemoglobins | 1 | 2019 | 1532 | 0.030 |
Why?
|
Radiotherapy Dosage | 1 | 2020 | 2925 | 0.030 |
Why?
|
Arrhythmias, Cardiac | 1 | 2023 | 2258 | 0.030 |
Why?
|
Piperazines | 1 | 2023 | 2546 | 0.030 |
Why?
|
Heart Rate | 1 | 2024 | 4218 | 0.030 |
Why?
|
Pregnancy | 2 | 2024 | 30179 | 0.030 |
Why?
|
Propensity Score | 1 | 2020 | 1971 | 0.030 |
Why?
|
Fatigue | 1 | 2019 | 1556 | 0.020 |
Why?
|
Cholesterol, LDL | 1 | 2021 | 2396 | 0.020 |
Why?
|
Severity of Illness Index | 2 | 2024 | 15965 | 0.020 |
Why?
|
Administration, Oral | 1 | 2020 | 4041 | 0.020 |
Why?
|
Endothelial Cells | 1 | 2024 | 3586 | 0.020 |
Why?
|
Dyspnea | 1 | 2019 | 1352 | 0.020 |
Why?
|
Obesity | 2 | 2024 | 13065 | 0.020 |
Why?
|
Chest Pain | 1 | 2018 | 1099 | 0.020 |
Why?
|
Contrast Media | 1 | 2024 | 5336 | 0.020 |
Why?
|
Cross-Sectional Studies | 2 | 2023 | 26351 | 0.020 |
Why?
|
Genetic Vectors | 1 | 2019 | 3417 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2019 | 6856 | 0.020 |
Why?
|
Cells, Cultured | 1 | 2024 | 19041 | 0.020 |
Why?
|
Animals | 2 | 2019 | 169418 | 0.020 |
Why?
|
Insurance, Health | 1 | 2021 | 2513 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2019 | 6537 | 0.020 |
Why?
|
Cerebral Hemorrhage | 1 | 2020 | 2665 | 0.020 |
Why?
|
Energy Metabolism | 1 | 2019 | 2901 | 0.020 |
Why?
|
Risk | 1 | 2020 | 9642 | 0.020 |
Why?
|
Inpatients | 1 | 2019 | 2561 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2019 | 5803 | 0.020 |
Why?
|
Health Status Disparities | 1 | 2019 | 1876 | 0.020 |
Why?
|
Anti-HIV Agents | 1 | 2023 | 4567 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2021 | 7863 | 0.020 |
Why?
|
Prevalence | 1 | 2024 | 15880 | 0.020 |
Why?
|
Heart Diseases | 1 | 2020 | 2816 | 0.020 |
Why?
|
Comorbidity | 1 | 2021 | 10601 | 0.020 |
Why?
|
ROC Curve | 1 | 2014 | 3624 | 0.020 |
Why?
|
Survival Analysis | 1 | 2018 | 10125 | 0.020 |
Why?
|
Patient Readmission | 1 | 2019 | 3308 | 0.020 |
Why?
|
Substance-Related Disorders | 1 | 2021 | 4453 | 0.010 |
Why?
|
Anticoagulants | 1 | 2020 | 4840 | 0.010 |
Why?
|
Smoking | 1 | 2020 | 9099 | 0.010 |
Why?
|
Apoptosis | 1 | 2019 | 9526 | 0.010 |
Why?
|
Research Design | 1 | 2017 | 6217 | 0.010 |
Why?
|
Electronic Health Records | 1 | 2017 | 4877 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2019 | 18388 | 0.010 |
Why?
|
Child, Preschool | 1 | 2022 | 42623 | 0.010 |
Why?
|
Stroke | 1 | 2020 | 9791 | 0.010 |
Why?
|